These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 36579617)

  • 1. Pediatric Population Pharmacokinetic Modeling and Exposure-Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data.
    Okour M; Thapar MM; Farrell C; Lukas MA; Beghetti M; Beerahee M
    J Clin Pharmacol; 2023 May; 63(5):593-603. PubMed ID: 36579617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
    Takatsuki S; Rosenzweig EB; Zuckerman W; Brady D; Calderbank M; Ivy DD
    Pediatr Pulmonol; 2013 Jan; 48(1):27-34. PubMed ID: 22511577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.
    Spence R; Mandagere A; Harrison B; Dufton C; Boinpally R
    J Pharm Sci; 2009 Dec; 98(12):4962-74. PubMed ID: 19455620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.
    Harrison B; Magee MH; Mandagere A; Walker G; Dufton C; Henderson LS; Boinpally R
    Clin Drug Investig; 2010; 30(12):875-885. PubMed ID: 20923245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study.
    Spence R; Mandagere A; Walker G; Dufton C; Boinpally R
    Clin Drug Investig; 2010; 30(5):313-24. PubMed ID: 20384387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
    Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
    BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.
    Ferguson-Sells L; Velez de Mendizabal N; Li B; Small D
    Clin Pharmacokinet; 2022 Feb; 61(2):249-262. PubMed ID: 34379314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension.
    Yoshida S; Shirato K; Shimamura R; Nakahara N; Iwase T; Nakajima H
    Curr Med Res Opin; 2011 Sep; 27(9):1827-34. PubMed ID: 21812736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
    Yoshida S; Shirato K; Shimamura R; Iwase T; Aoyagi N; Nakajima H
    Curr Med Res Opin; 2012 Jun; 28(6):1069-76. PubMed ID: 22506623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence and Tolerability of Ambrisentan: A Pharmacokinetic Study in Mexican Healthy Male Subjects.
    Cárdenas KPC; Velázquez JER; Escobar JJO; Chirinos J; Pendela M
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):611-618. PubMed ID: 32472357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I Study to Show the Relative Bioavailability and Bioequivalence of Fixed-Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects.
    Okour M; Puri A; Chen G; Port K; Berni A; Khindri S; Schneider I; Tenero D
    Clin Ther; 2019 Jun; 41(6):1110-1127. PubMed ID: 31060740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
    Zhao Q; Guo N; Chen J; Parks D; Tian Z
    J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension.
    Willmann S; Keller AK; Meyer M; van der Mey D; Wirsching G; Zhang Y; Drenth HJ; Keunecke A; Vendel E; Saleh S
    Pediatr Pulmonol; 2023 Mar; 58(3):908-917. PubMed ID: 36507572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
    Shapiro S; Pollock DM; Gillies H; Henig N; Allard M; Blair C; Anglen C; Kohan DE
    Am J Cardiol; 2012 Nov; 110(9):1373-7. PubMed ID: 22858181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
    Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
    BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.
    Walker G; Mandagere A; Dufton C; Venitz J
    Br J Clin Pharmacol; 2009 May; 67(5):527-34. PubMed ID: 19552747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.
    Badesch DB; Feldman J; Keogh A; Mathier MA; Oudiz RJ; Shapiro S; Farber HW; McGoon M; Frost A; Allard M; Despain D; Dufton C; Rubin LJ;
    Cardiovasc Ther; 2012 Apr; 30(2):93-9. PubMed ID: 21884013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic evaluation of ambrisentan.
    Buckley MS; Wicks LM; Staib RL; Kirejczyk AK; Varker AS; Gibson JJ; Feldman JP
    Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):371-80. PubMed ID: 21299444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
    Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Controlled Pharmacokinetic and Pharmacodynamics Trial of Ambrisentan After Fontan Surgery.
    Hill KD; Maharaj AR; Li JS; Thompson E; Barker PCA; Hornik CP
    Pediatr Crit Care Med; 2020 Sep; 21(9):e795-e803. PubMed ID: 32639468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.